Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study

Table 1 Summary of clinical events and treatment over time

Year	Event	Surgical debulking	Adjuvant chemotherapy	Allergology
2008	Stage III ovarian cancer of the endometrioid type	Yes	6 Cycles of carboplatin and paclitaxel
2009
2010	Disease relapse	Yes	No
2011
2012
2013	Disease relapse	Yes	No
2014	Symptomatic platinum-sensitive disease relapse	Not possible	2 Cycles of carboplatin/paclitaxel Cycle 3 omitted Cycle 4–6 according to 10-step desensitisation schedule	Cycle 2: allergic reaction Skin tests positive for carboplatin, negative for paclitaxel
2015
2016
2017	Symptomatic platinum-sensitive disease relapse	No	6 Cycles of carboplatin/paclitaxel according to 10-step desensitisation schedule	Skin tests positive for carboplatin
2018	Symptomatic platinum-sensitive disease relapse	No	6 Cycles of carboplatin monotherapy according to 10-step desensitisation schedule with additional omalizumab for cycle 4–6	Cycle 1: flushing, pruritus and erythema of the face and chest Cycle 2 + 3: Anaphylaxis Skin tests positive for carboplatin (negative for cisplatin) Cycle 4–6: Uneventful Skin tests persistently positive
2019	Symptomatic platinum-sensitive disease relapse	No	6 Cycles of carboplatin monotherapy according to 10-step desensitisation schedule with additional omalizumab	No events

ISSN: 2045-7022